Posted by Michael Wonder on 22 Feb 2020
UK deal over inclisiran
18 February 2020 - Government’s public enthusiasm looks premature given the lack of available data
The UK government recently announced an “innovative and ground-breaking collaboration” with the drug company Novartis to launch a clinical trial of inclisiran, a new cholesterol lowering drug.
In addition, health officials said that they would provide the “cutting edge new cholesterol treatment” to patients once it was approved by regulators and the National Institute for Health and Care Excellence.
They also stated that early results suggest that if 300 000 patients are treated each year, 55 000 heart attacks and strokes could be prevented and 30 000 lives saved over 10 years.
